Abiomed's Impella 2.5 now has an FDA indication for high-risk PCI.
March 24, 2015 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) clearance for Abiomed’s Impella 2.5 heart pump during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.
This additional FDA indication is based on the extensive clinical data submitted by Abiomed to the FDA to support this PMA as part of the 515 initiative. Impella 2.5, the world’s smallest heart pump, is the first hemodynamic support device to receive a PMA indication for use during high-risk PCI procedures, demonstrating its safety and effectiveness for this complex patient population.
With this approval, the Impella 2.5 is a temporary (6 hours or less) ventricular support device indicated for use during high-risk PCI performed in elective or urgent hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, Use is deteremined by a heart team, including a cardiac surgeon, when high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 in these patients may prevent hemodynamic instability that may occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.
The product labeling allows for the clinical decision to leave Impella 2.5 in place beyond the intended duration of less than 6 hours due to unforeseen circumstances.
Per the 2011 ACC/AHA guidelines, it is a Class 1 recommendation for a heart team, which includes a cardiac surgeon, to determine the treatment strategy for revascularization (either PCI or surgery). This decision is made based on a pre-defined institutional protocol or on a per patient basis. If the protocol determines that PCI is appropriate, Impella is the only hemodynamic support device proven safe and effective for high-risk PCI. This heart team approach has also been utilized for the treatment strategy for heart valve replacement.
“The rigorous data from FDA clinical trials such as PROTECT I and PROTECT II demonstrate that complex, high-risk patients undergoing protected PCI with Impella 2.5 support experience reduced adverse events, improved quality of life and are able to return home faster with fewer repeat procedures,” said William O’Neill, M.D., Henry Ford Hospital in Detroit. “The heart team approach has evolved into a mainstream practice recognized by the guidelines for determining the need for PCI versus surgery and will continue to act as a platform for the screening and determination of the appropriate revascularization treatment for this high risk patient population.”
In addition to the U.S. clinical trial data, the Impella 2.5 PMA submission included clinical and scientific supporting evidence from more than 215 publications, totaling 1,638 Impella 2.5 patients and incorporated a medical device reporting (MDR) analysis from 13,981 Impella 2.5 patients.
In addition to PROTECT I and PROTECT II, further data was provided in the submission from 637 high-risk patients enrolled in the U.S. Impella registry. The U.S. registry is an ongoing multicenter, observational retrospective registry including 49 centers. The data collection from the registry includes Institutional Review Board (IRB) approval, complete data monitoring and Clinical Events Committee adjudication. PMA analysis included hemodynamic science described in the literature and validated with a series of pre-clinical and clinical studies.
“As heart disease patients get sicker, more complex, and desire minimally invasive solutions, there are few options available to them to help improve their quality of life in a cost effective manner,” said Michael Minogue, chairman, president and chief executive officer, Abiomed. “We are excited that Impella has been recognized as a device that can potentially become the new standard of care with a ‘first of its kind’ approval.”
The Impella System
The Impella 2.5 received 510(k) clearance from the FDA in 2008, is supported by clinical guidelines and has been reimbursed by the Centers for Medicare and Medicaid Services (CMS) under ICD-9-CM code 37.68 since 2008 for multiple indications, including high-risk PCI. The Impella product portfolio, which also includes the Impella CP, Impella RP and Impella 5.0, has supported more than 25,000 patients in the United States.
Per the regulatory process, Abiomed will conduct a single arm, post approval study on the Impella 2.5, collecting data on high-risk PCI patients. The Impella CP and Impella 5.0 will be submitted in the future as PMA supplements and will retain their 510(k) clearances until completion of the FDA process. The Impella RP device received Humanitarian Device Exemption (HDE) approval in January 2015. For the Impella RP Launch, the hospital heart team will be hosted at company headquarters for a rigorous certification process followed by on-site training at their hospital.
For more information: www.abiomed.com